Clinical significance of tumor marker NCC-ST 439 in large bowel cancers |
| |
Authors: | Dr. Akio Yamaguchi M.D. Yoshiyuki Kurosaka M.D. Tetsuya Ishida M.D. Genichi Nishimura M.D. Masahiro Kanno M.D. Takeo Kosaka M.D. Yutaka Yonemura M.D. Itsuo Miyazaki M.D. |
| |
Affiliation: | (1) Department of Surgery II, School of Medicine, Kanazawa University, 13-1 Takaramachi, Kanazawa, 920 Ishikawa, Japan |
| |
Abstract: | We examined serum NCC-ST 439 for its significance as a tumor marker of large bowel cancer in 121 patients with primary and 36 with recurrent large bowel cancer. Serum NCC-ST 439 was positive in 27.3 percent of the former and 66.7 percent of the latter. It was false-positive in only 5.6 percent of patients with benign diseases. Positive serum NCC-ST 439 correlated with lymph node and liver metastases. The combination assay for NCC-ST 439, CEA, and CA19-9 was positive in 49.6 percent of the patients with primary tumors and 88.9 percent of those with recurrent tumors; in other words, the diagnostic accuracy improved. The results demonstrated that the determination of serum NCC-ST 439 in large bowel cancer might be useful in cancer staging and that NCC-ST 439, if used in combination with CEA, is particularly useful in diagnosing recurrences because of its improved diagnostic accuracy. |
| |
Keywords: | NCC-ST 439 CEA CA19-9 Tumor marker Colorectal cancer |
本文献已被 SpringerLink 等数据库收录! |
|